- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Approves Sotatercept for Pulmonary Arterial Hypertension
Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies.
EP: 1.Evolving Guidelines for PAH Treatment
EP: 2.New Therapeutic Frontiers in PAH
EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management
EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension
EP: 5.Breaking Down the PAH Cost Burden
EP: 6.A New Era in PAH Treatment?
EP: 7.Clinical Evidence for Emerging PAH Therapies
EP: 8.Integrating New PAH Therapies into Clinical Practice
EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes
EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension
EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH
EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches
EP: 13.Optimizing PAH Care Delivery for Better Outcomes
EP: 14.Addressing Unmet Needs in the PAH Landscape
Video content above is prompted by the following question(s):
- What is the mechanism of action for the recent FDA-approved drug sotatercept and how does it differ from existing pulmonary arterial hypertension (PAH) therapies?
- Given that sotatercept is currently approved as an add-on therapy, what potential cost implications should payers and health systems consider?
- Is sotatercept being studied as a foundational therapy for PAH? If so, what potential advantages or disadvantages could it offer compared to existing foundational therapies?
Lung Transplant Referrals Lag for High-Risk Patients With PAH
July 18th 2025Despite recommendations on early referral for lung transplantation in cases of pulmonary arterial hypertension (PAH), there is a lack of in-depth understanding of this current landscape; in this analysis, clinical parameter data were used to compare outcomes between patients who were and were not referred for lung transplantation.
Read More
Family Key to PAH Care for Women, but Gaps Remain
June 18th 2025This study highlights the vital role of caregivers in supporting women living with pulmonary arterial hypertension (PAH) and underscores the need to enhance caregiver support and address unmet needs to improve patient outcomes.
Read More
